View ValuationBioextrax 将来の成長Future 基準チェック /06現在、 Bioextraxの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Machinery 収益成長24.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 24First quarter 2026 earnings released: kr0.094 loss per share (vs kr0.10 loss in 1Q 2025)First quarter 2026 results: kr0.094 loss per share. Net loss: kr4.33m (loss widened 8.6% from 1Q 2025).Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Fredrik Sjodin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 07Bioextrax AB (publ), Annual General Meeting, May 21, 2026Bioextrax AB (publ), Annual General Meeting, May 21, 2026.お知らせ • Oct 25Bioextrax AB (publ), Annual General Meeting, May 22, 2025Bioextrax AB (publ), Annual General Meeting, May 22, 2025.Reported Earnings • Aug 21Second quarter 2024 earnings released: kr0.15 loss per share (vs kr0.22 loss in 2Q 2023)Second quarter 2024 results: kr0.15 loss per share (improved from kr0.22 loss in 2Q 2023). Net loss: kr4.80m (loss narrowed 13% from 2Q 2023).New Risk • Aug 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.63m (US$9.46m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 44% per year over the past 5 years. Revenue is less than US$1m (kr2.2m revenue, or US$204k). Market cap is less than US$10m (€8.63m market cap, or US$9.46m). Minor Risk Shareholders have been diluted in the past year (35% increase in shares outstanding).Reported Earnings • May 20First quarter 2024 earnings released: kr0.17 loss per share (vs kr0.17 loss in 1Q 2023)First quarter 2024 results: kr0.17 loss per share (further deteriorated from kr0.17 loss in 1Q 2023). Revenue: kr203.0k (down 81% from 1Q 2023). Net loss: kr4.87m (loss widened 15% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 18Full year 2023 earnings released: kr0.81 loss per share (vs kr1.11 loss in FY 2022)Full year 2023 results: kr0.81 loss per share. Revenue: kr3.01m (up 37% from FY 2022). Net loss: kr21.5m (loss widened 15% from FY 2022).Reported Earnings • Nov 19Third quarter 2023 earnings released: kr0.21 loss per share (vs kr0.30 loss in 3Q 2022)Third quarter 2023 results: kr0.21 loss per share. Net loss: kr5.50m (loss widened 20% from 3Q 2022).Board Change • Sep 01No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Per Hokfelt was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.New Risk • Aug 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.09m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Revenue is less than US$1m (kr2.8m revenue, or US$261k). Market cap is less than US$10m (€9.09m market cap, or US$9.91m).New Risk • Jul 07New major risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €9.93m (US$10.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Revenue is less than US$1m (kr2.8m revenue, or US$262k). Minor Risk Market cap is less than US$100m (€9.93m market cap, or US$10.9m).Reported Earnings • Feb 18Full year 2022 earnings released: kr1.11 loss per share (vs kr0.74 loss in FY 2021)Full year 2022 results: kr1.11 loss per share (further deteriorated from kr0.74 loss in FY 2021). Net loss: kr18.7m (loss widened 77% from FY 2021).Recent Insider Transactions • Jan 17CTO & Director recently sold €58k worth of stockOn the 13th of January, Mohammad H. Ibrahim sold around 200k shares on-market at roughly €0.29 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Dec 02Third quarter 2022 earnings releasedThird quarter 2022 results: Net loss: kr4.60m (loss widened 80% from 3Q 2021).Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Per Hokfelt was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.お知らせ • Oct 31Bioextrax AB (publ) to Report Q3, 2022 Results on Nov 29, 2022Bioextrax AB (publ) announced that they will report Q3, 2022 results on Nov 29, 2022お知らせ • Aug 02Bioextrax AB (publ) to Report Q2, 2022 Results on Aug 31, 2022Bioextrax AB (publ) announced that they will report Q2, 2022 results on Aug 31, 2022お知らせ • May 31Bioextrax AB (publ), Annual General Meeting, Jun 28, 2022Bioextrax AB (publ), Annual General Meeting, Jun 28, 2022.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Member of Advisory Board Jan Ravenstijn was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 26Bioextrax AB (publ) to Report Q1, 2022 Results on May 25, 2022Bioextrax AB (publ) announced that they will report Q1, 2022 results on May 25, 2022 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Bioextrax は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:85X0 - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261-18-13-13N/A12/31/20251-18-26-26N/A9/30/20251-17-15-15N/A6/30/20251-16-16-15N/A3/31/20251-16-18-18N/A12/31/20241-17-19-19N/A9/30/20242-20-18-18N/A6/30/20242-21-21-21N/A3/31/20242-22-23-22N/A12/31/20233-22-24-23N/A9/30/20233-21-26-19N/A6/30/20233-20-21-14N/A3/31/20233-20-26-19N/A12/31/20222-19-24-18N/A9/30/20222-16-21-20N/A6/30/20222-14-22-21N/A3/31/20221-11-12-12N/A12/31/20211-11-9-8N/A9/30/20210-10-8-7N/A6/30/20210-8-6-5N/A3/31/20210-7-7-6N/A12/31/20200-6-4-4N/A9/30/20200-4-5-5N/A6/30/20201-4-5-4N/A3/31/20201-2-4-3N/A12/31/20191-2N/A-3N/A12/31/20181-1N/A1N/A12/31/201710N/A0N/A12/31/201600N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 85X0の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 85X0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 85X0の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 85X0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 85X0の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 85X0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 02:18終値2026/05/27 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioextrax AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 24First quarter 2026 earnings released: kr0.094 loss per share (vs kr0.10 loss in 1Q 2025)First quarter 2026 results: kr0.094 loss per share. Net loss: kr4.33m (loss widened 8.6% from 1Q 2025).
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Fredrik Sjodin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 07Bioextrax AB (publ), Annual General Meeting, May 21, 2026Bioextrax AB (publ), Annual General Meeting, May 21, 2026.
お知らせ • Oct 25Bioextrax AB (publ), Annual General Meeting, May 22, 2025Bioextrax AB (publ), Annual General Meeting, May 22, 2025.
Reported Earnings • Aug 21Second quarter 2024 earnings released: kr0.15 loss per share (vs kr0.22 loss in 2Q 2023)Second quarter 2024 results: kr0.15 loss per share (improved from kr0.22 loss in 2Q 2023). Net loss: kr4.80m (loss narrowed 13% from 2Q 2023).
New Risk • Aug 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.63m (US$9.46m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 44% per year over the past 5 years. Revenue is less than US$1m (kr2.2m revenue, or US$204k). Market cap is less than US$10m (€8.63m market cap, or US$9.46m). Minor Risk Shareholders have been diluted in the past year (35% increase in shares outstanding).
Reported Earnings • May 20First quarter 2024 earnings released: kr0.17 loss per share (vs kr0.17 loss in 1Q 2023)First quarter 2024 results: kr0.17 loss per share (further deteriorated from kr0.17 loss in 1Q 2023). Revenue: kr203.0k (down 81% from 1Q 2023). Net loss: kr4.87m (loss widened 15% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 18Full year 2023 earnings released: kr0.81 loss per share (vs kr1.11 loss in FY 2022)Full year 2023 results: kr0.81 loss per share. Revenue: kr3.01m (up 37% from FY 2022). Net loss: kr21.5m (loss widened 15% from FY 2022).
Reported Earnings • Nov 19Third quarter 2023 earnings released: kr0.21 loss per share (vs kr0.30 loss in 3Q 2022)Third quarter 2023 results: kr0.21 loss per share. Net loss: kr5.50m (loss widened 20% from 3Q 2022).
Board Change • Sep 01No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Per Hokfelt was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
New Risk • Aug 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.09m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Revenue is less than US$1m (kr2.8m revenue, or US$261k). Market cap is less than US$10m (€9.09m market cap, or US$9.91m).
New Risk • Jul 07New major risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €9.93m (US$10.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Revenue is less than US$1m (kr2.8m revenue, or US$262k). Minor Risk Market cap is less than US$100m (€9.93m market cap, or US$10.9m).
Reported Earnings • Feb 18Full year 2022 earnings released: kr1.11 loss per share (vs kr0.74 loss in FY 2021)Full year 2022 results: kr1.11 loss per share (further deteriorated from kr0.74 loss in FY 2021). Net loss: kr18.7m (loss widened 77% from FY 2021).
Recent Insider Transactions • Jan 17CTO & Director recently sold €58k worth of stockOn the 13th of January, Mohammad H. Ibrahim sold around 200k shares on-market at roughly €0.29 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Dec 02Third quarter 2022 earnings releasedThird quarter 2022 results: Net loss: kr4.60m (loss widened 80% from 3Q 2021).
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Per Hokfelt was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
お知らせ • Oct 31Bioextrax AB (publ) to Report Q3, 2022 Results on Nov 29, 2022Bioextrax AB (publ) announced that they will report Q3, 2022 results on Nov 29, 2022
お知らせ • Aug 02Bioextrax AB (publ) to Report Q2, 2022 Results on Aug 31, 2022Bioextrax AB (publ) announced that they will report Q2, 2022 results on Aug 31, 2022
お知らせ • May 31Bioextrax AB (publ), Annual General Meeting, Jun 28, 2022Bioextrax AB (publ), Annual General Meeting, Jun 28, 2022.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Member of Advisory Board Jan Ravenstijn was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 26Bioextrax AB (publ) to Report Q1, 2022 Results on May 25, 2022Bioextrax AB (publ) announced that they will report Q1, 2022 results on May 25, 2022